Natixis Advisors LLC Acquires 1,997 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Natixis Advisors LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,171 shares of the company's stock after purchasing an additional 1,997 shares during the quarter. Natixis Advisors LLC owned approximately 0.06% of IDEXX Laboratories worth $18,675,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IDXX. Atala Financial Inc bought a new position in IDEXX Laboratories during the 4th quarter worth approximately $102,000. Lazard Freres Gestion S.A.S. acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $20,309,000. Skandinaviska Enskilda Banken AB publ raised its stake in IDEXX Laboratories by 11.2% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 18,913 shares of the company's stock worth $7,806,000 after buying an additional 1,900 shares during the last quarter. Erste Asset Management GmbH lifted its holdings in IDEXX Laboratories by 17.9% in the fourth quarter. Erste Asset Management GmbH now owns 3,290 shares of the company's stock valued at $1,365,000 after buying an additional 500 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in IDEXX Laboratories by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 453 shares of the company's stock valued at $187,000 after acquiring an additional 201 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Remove Ads

IDEXX Laboratories Stock Up 0.1 %

Shares of IDEXX Laboratories stock traded up $0.37 during trading hours on Friday, reaching $420.99. The company's stock had a trading volume of 706,610 shares, compared to its average volume of 550,872. The company has a market capitalization of $34.12 billion, a P/E ratio of 39.46, a P/E/G ratio of 3.41 and a beta of 1.39. The stock's fifty day simple moving average is $437.36 and its two-hundred day simple moving average is $445.11. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IDXX shares. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price for the company. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.